Advancing Biomedical Research through Global Collaborations

Drug Discovery & Development

Asia Pacific

June 1-3, 2005
Shangri-La Hotel
Singapore

In Association with:

Distinguished Faculty

Australia
Alison Coutts, EG Capital

Austria
Klaus K. Wilgenbus, Ph.D., Boehringer-Ingelheim

China
William Xia Guo, MSc., VenturePharm Group
Ge Li, Ph.D., WuXi Pharmatech
Sam Lou, MBA, Crimson Pharmaceuticals
Wang Ting, Ph.D., State FDA
Kan Zu, Unitalen Attorneys at Law

Germany
Udo Huber, Agilent Technologies
Kurt A. Stoeckli, Ph.D., Sanofi-Aventis

India
Anantha N. Nagappa, Ph.D., Birla Institute of Technology & Science
Harvinder Popli, Ph.D., Ranbaxy Laboratories Ltd

Japan
Fumio Suzuki, Kyowa Hakko Kogyo

Korea
Michael Park, Ph.D., Bioneer Corporation

Malaysia
Mahendra Panagarah, Altana Pharma

Singapore
Tony Buss, Ph.D., Merlion Pharmaceuticals
Mun Ching Kan, Covance (Asia) Pte Ltd
Alex Matter, M.D., Novartis Institute for Tropical Disease
Mae Shieh, Novartis Institute for Tropical Disease
Patrick Tan, M.D., Ph.D., National Cancer Center of Singapore
Anand Tharmaratnam, M.D, Quintiles

Switzerland
Gianni Gramo, Ph.D., E. Hoffmann-La Roche
Khalil Islam, Ph.D., Arpida Ltd
Frank Petersen, Ph.D., Novartis Pharma AG

Keynote Presentations

Thursday June 2, 2005

• Kurt Stoeckli, Ph.D.,
  Vice President, Global Lead Discovery,
  Sanofi-Aventis, Germany

• Klaus Wilgenbus, Ph.D.,
  Head, Corporate Division Licensing,
  Boehringer-Ingelheim, Austria

Friday, June 3, 2005

• Ismail Kola, Ph.D.,
  SVP Basic Research,
  Merck Research Laboratories, United States

• Gianni Gromo, M.D,
  Head of Discovery Research, Basel,
  F. Hoffmann-La Roche Ltd., Switzerland

Gain Insights into:

• IP, Patents and Regulatory Challenges in Asia
• Successful East-West Partnering Strategies
• Technology Transfer & Commercialization of Research
• Scientific Advances in Cancer, Infectious Diseases, CNS, and Cardiovascular Diseases
• Cutting-edge Biotherapeutics
• Natural Product Drug Discovery
• Conducting Clinical Trials in Asia

www.drugdisc.com

Distinguished Faculty

Taiwan
Rong Hwa Lin, Ph.D., AbGenomics Corporation

United Kingdom
Paul J. Clewlow, Ph.D., Pharmaceutical Profiles Ltd
Denise Pollard Knight, Ph.D., Nomura International Inc.
Miroslav Ravic, M.D, Ph.D., Antisoma
Karol Sikora, M.D, Ph.D., Imperial College & Hammersmith Hospital
Alan Warrander, Ph.D., AstraZeneca

United States
Lee F. Allen, M.D, Ph.D., Wyeth Research
Connie Andrews, M.A., MedImmune Inc.
E. Morrey Atkinson, Ph.D., Eli Lilly & Co.
William H. Balke, Ph.D., Elsevier MDL
Akiko Futamura, Ph.D., SC Biosciences
Joydeep Goswami, Ph.D., MSc., Invitrogen Corporation
Deborah Hartman, Ph.D., AstraZeneca Pharmaceuticals LP
Ismail Kola, Ph.D., Merck Research Labs
Patrick Y. Lu, Ph.D., Intradigm Corporation
Yan-Gao Man, M.D, Ph.D., Armed Forces Institute of Pathology
Krishna Menon, Ph.D., KARD Scientific Inc.
Richard Soll, Ph.D., TargeGen
Rebecca Taub, M.D., Hoffman-La Roche Inc.
YuGuang Wang, Ph.D., Schering-Plough Research Institute
James Xue, Ph.D., MBA, Genzyme Corporation
Guo Liang Yu, Ph.D., Epitomics Inc.
Harry (Hong) Zhang, Ph.D., Z-BioMed Inc.
Li Zhu, Ph.D., Genetastix Corporation

Organized by:

Supported by:

Event Partners:
The Premier Asia-Pacific Pharma/Biotech Meeting Place!

With the rapid advancements in biomedical research and technological capabilities in Asia Pacific, new opportunities are emerging for potential collaborations in discovery chemistry, biopharmaceutical therapeutics and clinical trials between US and European pharmaceutical and biotech companies and those from China, India, Singapore, Japan and other Asia-Pacific countries.

Featuring over 40 internationally renowned speakers from 13 countries, and an exhibit hall displaying the latest and brightest in technologies, products and services, this Congress and Exhibition is one you cannot afford to miss.

Produced by the organizers of the Drug Discovery Technology® World Congress, the Drug Discovery & Development Asia-Pacific Congress will take an in-depth look at the innovative progress being made by various Asia-Pacific countries. Conference speakers will present case studies of successful East-West collaborations and lessons learned in the Asian market, as well as deliver scientific updates on disease-specific drug discovery and research.

Whether you are an Asia Pacific company, eager for innovative scientific updates or searching for outsourcing opportunities; or a Western pharma or biotech company looking at the plethora of opportunities that abound in Asia, such as finding new molecules to in-license or forming research partnerships, this Congress has it all.

We encourage you to register today and start making contacts through the Partnering Zone, a pre-event partnering service for registered attendees.

Partnering Zone – A FREE Pre-Event Partnering Service for Attendees

All registered attendees of this conference will have access to the Partnering Zone, an on-line partnering service offered in advance of the event. Attendees will receive a password by e-mail for the Partnering Zone portion of the event website. Users will be asked to provide a company profile, a summary of partnering goals and a contact e-mail, which will then be listed on the Partnering Zone web page. Attendees can select partners of interest and make e-mail contact before the conference.

Media Partners

SCRIP World Pharmaceutical News
www.scrippharma.com

Pacific Bridge, Inc. – Asian Medical eNewsletter
www.pacificbridgeme.com

BioTechniques
www.biotechniques.com

BioProcess International™
www.bioprocessintl.com

D&MD Publications
www.drugandmarket.com

Combinatorial Chemistry & High Throughput Screening
www.bentham.org/cchts

Current Drug Targets
www.bentham.org/cdt

Current Medicinal Chemistry
www.bentham.org/cmc

Current Pharmaceutical Design
www.bentham.org/cpd

Current Drug Metabolism
www.bentham.org/cdm

CombiChem.net
www.combichem.net

GenomicsProteomics.com
www.genomicsproteomics.com

HTScreening.net
www.htscreening.net

SelectScience.net
www.selectscience.com

Supported By

IBC gratefully acknowledges the Singapore Economic Development Board for its assistance and support for the Drug Discovery and Development Asia Pacific Congress

Call for Posters

Present Your Poster at Drug Discovery & Development Asia Pacific and Gain the Notice of Fellow Scientists and Industry Peers!

The organizers of Drug Discovery & Development Asia Pacific Congress recognize the significant educational value in the poster presentations.

Any registered attendee may sign up to present a poster. The deadline to submit your abstract online, at www.drugdisc.com/3110/posters, is May 6, 2005, for the accepted poster to be included in the Conference Handbook (see the registration page for details on the poster fee). The size of the poster board is 1.8m (6’)H x .7m (2.5’)W.

Please note: Poster presentations may not be used as exhibit displays or for marketing purposes. All posters are subject to approval by conference organizers. Poster abstracts must be submitted online at www.drugdisc.com/3110/posters

China Biotech 2004 Directory

The China Biotech 2004 Directory of Companies provides an overview of research and development in the life sciences in China. Produced by General Biologic, a professional services firm focused on bio-business in China, GB provides information products, management consulting, and transactional services to clients involved in biotechnology, pharmaceuticals, investment, and laboratory supply. To order this directory for only US$300, please contact Renée Marks at (508) 616-5550 Ext. 429 or by e-mail at: rm@drugandmarket.com
Wednesday, June 1, 2005

Business Strategies & Successful Collaborations

7:00 Registration & Breakfast Bakeries

8:20 Chairman’s Opening Remarks
Alan Warrander, Ph.D., Director, Global Licensing, AstraZeneca, UK

8:30 Congress Opening Address
Senior Official, Government of Singapore

Strategies And Case Studies of Successful Alliances, Licensing & Outsourcing Partnerships

9:00 Pharmaceutical Promotional Alliances: Co-Promotion vs. Co-Marketing
With the globalization of markets, increasing financial pressures, struggling product pipeline and implementation of the patent regime in the Indian Pharma market, pharmaceutical companies are under pressure to find revenue growth. Co-promotion and co-marketing with other pharmaceutical companies provide opportunities for utilizing the capabilities optimally. Mastering the skill to attract great partners and to execute high performing alliance is an important area that companies should cultivate in the future.
Harvinder Popli, Ph.D., Head Licensing (India), Ranbaxy Labs, India

9:25 Successful Partnering – the Case for Licensing
In the risky business arena of Pharmaceuticals, why should companies increase risks by partnering? Clearly, partnering, either through licensing or any other partnering structure helps to spread the risk, provide additional expertise, financing or validation. This presentation will discuss these aspects with some case study examples.
Alan Warrander, Ph.D., Director, Global Licensing, AstraZeneca, UK

9:50 Globalization of R&D Through Effective Partnerships
The unique mission and business model of the Novartis Institute for Tropical Diseases (NITD) requires it to establish effective collaborations and partnerships across the globe, including non-profit groups, academic/ institutes/biotech and its own research affiliates of Novartis. This talk will provide an overview on how NITD has selected and established its current collaborations and its global partnership strategy for the future.
Mae Shieh, Head, Global Partnerships, Novartis Institute for Tropical Diseases (NITD), Singapore

10:15 Opening of Exhibit & Poster Hall & Networking Refreshment Break

11:00 Opportunities for Outsourcing of Integrated Pharmaceutical Development in China
Pharma companies are heavily relying on outsourcing to help them meet the growing demand and to bring new drugs to market quickly and more economically. The World is turning its attention to China and other Asian countries for this regard. This presentation will explore the opportunities for outsourcing in China, and will illustrate an example of VenturePharm’s collaborative efforts in outsourcing with a foreign partner.
William Xia Guo, MSc., Chief Executive Officer, VenturePharm Group, China

11:25 Creating and Managing New Collaborative Outsourcing Paradigms in Drug Discovery: A Small Company Chemistry Viewpoint from Lead Generation to Multi-Kilo Scale
In this joint presentation, we discuss a new chemistry paradigm for collaborative chemistry outsourcing as illustrated by the collaboration between TargetGen and WuXi Pharmatech. This has accelerated the rapid discovery of a compound now advancing towards clinical development and has created a deep drug candidate portfolio. We will discuss and illustrate numerous facets which have factored into this successful partnership including (a) identifying key chemistry technologies, capabilities and bandwidth in collaborative outsourcing, (b) choosing a viable collaborative format, (d) managing the expectations and deliverables of the relationship, and (d) driving towards results-oriented productivity, customer satisfaction and success for both organizations.
Ge Li, Ph.D., Chief Executive Officer, WuXi PharmaTech, China
Richard M. Soll, Ph.D., Chief Scientific Officer, Re-3, TargetGen, USA

11:50 Strategies for Pre-Clinical Out-sourcing
• Areas: Chemistry, in vitro and in vivo efficacy and efficiency testing, ADME and toxicology
• Knowledge based: Ethnic medicines of the area, and the many failures in development recently. Development of nutraceuticals in drug development
• Availability of both scientists and natural ingredients/products in abundance
• Cost efficiency
• Friendly regulations in research and development
Krishna Menon, Ph.D, President & CEO, KARD Scientific Inc., USA/India

12:15 Advancing Healthcare Biotechnology without Borders
With its capabilities and potential, Asia is destined to play an instrumental role in the global development of healthcare biotechnology. By working with partners including companies, physicians, patients group, academic institutions, non-profit organizations and government agencies, Genzyme is helping to reshape the landscape of the healthcare market in Asia, especially in the rare diseases area.
James Q. Xue, Ph.D., MBA, Director of Commercial Operations and Market Development, Asia Pacific Group, Genzyme Corporation, USA

12:40 Networking Luncheon in Exhibit & Poster Hall

Navigating IP & Patents Challenges

2:00 Chairman’s Opening Remarks
Saresh Sachi, Director, Legal, A*STAR, Singapore

2:05 Adaptation of US FDA Guidelines for the Regulatory Approvals in China
This presentation will give an overview of how the SFDA has adapted US FDA guidelines for the regulatory approvals of new drugs in China.
Wang Ting, Ph.D., Department One, Center for Drug Evaluation, SFDA, China

2:30 Licensing and Developing Novel Therapeutics in China - Current Regulatory and IP Environment
The process of taking a new drug to market has become increasingly time consuming and capital intensive. Licensing and developing novel therapeutics in China have shown attractive advantages but come with some concerns. Strategies and practices will be discussed based upon Crimson’s unique experiences to develop IP protected new drug candidates in China through licensing and co-development arrangement.
Sam Lou, MBA, Chief Operating Officer, Crimson Pharmaceutical, China

2:55 Enforcement of Patents in China
How to enforce a patent in China becomes a critical issue among foreign companies, which have or will have patents in China. The patent enforcement environment in China has significantly changed compared to several years ago, and has been improving from time to time. A patentee may obtain preliminary injunction and would prevail in a court based on either literal infringement or doctrine of equivalents. Damages would be awarded if the infringement exists.
Kan Zu, Partner, Unitalen Attorneys At Law, China

3:20 Networking Refreshment Break in Exhibit & Poster Hall

Visit www.drugdisc.com/3110 for up-to-date information on this event


Wednesday, June 1, 2005

Harnessing Academic Research for Technology Transfer & Commercial Applications

3:50 S. pombe Deletion Library: High-Throughput Drug Target Screening
A deletion library of Schizosaccharomyces pombe, a fission yeast with many homologs to human disease-related genes, has been completed. Based on haploinsufficiency, it is possible to use the S. pombe deletion library for the screening of novel drug targets, identification of action mechanism of drugs, and early stage toxicity screening. Commercialization of high-throughput drug target screening services and site licensing opportunities will also be discussed.

Michael Park, Ph.D., Vice President, Bioneer Corporation, Korea

4:15 Licensing & Technology Transfer—Maximizing Returns from Research
Out-licensing technologies to the right partner can create significant value – to the inventors, partners and the scientific community. This presentation provides an understanding of the typical evaluation processes and licensing organization structures at licensees, examines some common bottlenecks in the licensing process and suggests some best practices to maximize value to all sides. The presentation will also highlight some of the more specific challenges facing licensing activities in Asia.

Joydeep Goswami, Ph.D., Director, Global Head of In-Licensing, Invitrogen Corp., USA

Thursday, June 2, 2005

Scientific Symposium

7:30 Registration & Breakfast Bakeries

8:20 Chairman’s Opening Remarks

Karol Sikora, M.D., Ph.D., Professor of Cancer Medicine, Hammersmith Hospital, London and Scientific Director, Medical Solutions PLC, UK

8:30 Keynote Address

Pharmaceutical Discovery: Productivity Gaps and the Strategic Shift Towards Quality, Integrated Sciences & Knowledge-Driven Networks

This talk will focus on complementary discovery approaches and highlight the value of in silico based predictive models and knowledge-driven networks. The timely delivery of novel high quality compounds useful for early animal and clinical studies remains the top priority, and the orchestration of innovation, operational efficiency and risk control is key to it. Recent improvements in efficiency have not translated into higher productivity as measured by the pipelines of development candidates. Downstream functions can often not take full advantage of the abundance of potentially attractive targets or chemical matters identified. The realignment of traditional research processes is one of the consequences. The changing landscape of Asia’s pharma and biotech industries will be mentioned in this context.

Kurt A. Stoeckli, Vice President, Global Head of Lead Identification Technologies, Discovery Research, Sanofi-Aventis, Germany

Disease-Specific Drug Discovery – Fulfilling the Unmet Medical Needs of Asia

9:00 Revolutionizing Cancer Therapy

The significant breakthrough in cancer treatment will result from the appropriate application of emerging technologies, e.g., pharmacogenomics, proteomics, etc., that will permit the identification of a responder profile or molecular signature predicting response. This will provide the catalyst for radical change and the advent of "personalized medicine," which will revolutionize cancer therapy.

Lee F. Allen, M.D., Ph.D., Cambridge Site Head, Vice President, Medical Research, Oncology Therapeutic Area, Wyeth Research, USA

9:25 The Challenge of Personalised Medicine for Cancer

Because the precise targets of new cancer drugs are known, there will be a revolution in how we prescribe them. Instead of defining drugs for use empirically and relatively ineffectively for different types of cancer, we will identify a series of molecular lesions in tumour biopsies. Sophisticated diagnostics using biomarkers and surrogates will be essential components of future patient care.

Karol Sikora, Ph.D., Professor of Cancer Medicine, Hammersmith Hospital, London, Scientific Director, Medical Solutions PLC, UK

9:50 Molecular Diagnostics of Cancer in the Asia Pacific Region

Cancer is a leading cause of global morbidity and mortality. Using examples from our research group, we will discuss how genome-wide profiling technologies such as DNA microarrays are radically transforming many aspects of both and clinical cancer research, providing novel insights into cancer gene function, disease prognosis, and drug treatment effects in human patients.

Patrick Tan Boon Ooi, M.D., Ph.D., Principal Investigator, Cellular and Molecular Research, National Cancer Center of Singapore and Group Leader, Genome Institute of Singapore, Singapore

10:15 Networking Refreshment Break in Exhibit & Poster Hall

10:45 Localized Myoepithelial And Basal Cell Degenerations and Resultant Immunoreactions are a Trigger Factor for Breast and Prostate Tumor Invasion: Implications for Drug Development and Treatment

Cancer invasion is traditionally attributed to basement membrane degradations by up-regulated proteolytic enzymes, whereas results from clinical trials with corresponding inhibitors have been very disappointing. Our studies reveal that breast and prostate cancer invasion is triggered by localized myoepithelial or basal cell degenerations and resultant immunoreactions. Thus, development of specific reagents to manipulate related immunoreactions may have better therapeutic values.

Yan-Gao Man, M.D., Ph.D., Department of Gynecologic and Breast Pathology, Armed Forces Institute of Pathology and American Registry of Pathology, USA

5:05 Panel Discussion: Investing and Financing Asia’s Life Sciences Development

Panelists:

Akiko Futamura, Ph.D., Vice President, SC BioSciences, USA
Linda Powers, Managing Director, Toucan Capital Corp., USA
Alison Coutts, Director, EG Capital, Australia
Denise Pollard-Knight, Ph.D., Head of Nomura Phase4 Ventures, Nomura International plc, UK

5:30 Close of Day One

Investments & Portfolio Management

4:40 Portfolio Management Based on Expected Present Value in R & D

Under limited budget, we have to prioritize some of R & D projects (go or not go) and decide in a timely to license-in or license-out several projects. In order to decide such options, we have to evaluate all projects in the common criteria such as expected present value. This presentation will describe how to calculate expected present value in R&D and other projects.

Fumio Suzuki, Senior Executive Officer, Strategy Planning, Kyowa Hakko Kogyo Co., Ltd, Japan

9:00 Revolutionizing Cancer Therapy

The significant breakthrough in cancer treatment will result from the appropriate application of emerging technologies, e.g., pharmacogenomics, proteomics, etc., that will permit the identification of a responder profile or molecular signature predicting response. This will provide the catalyst for radical change and the advent of “personalized medicine,” which will revolutionize cancer therapy.

Lee F. Allen, M.D., Ph.D., Cambridge Site Head, Vice President, Medical Research, Oncology Therapeutic Area, Wyeth Research, USA
11:10 Glucokinase Activators: Potential Novel Therapy for Type 2 Diabetes

GKAs augment both hepatic glucose metabolism and glucose stimulated insulin release (GSIR) from isolated rodent islets, consistent with the expression and function of GK in both cell types. In rodent models of type 2 diabetes, GKAs lower basal blood glucose levels, improve glucose tolerance and increase hepatic glucose uptake. GKAs are being developed as an oral treatment for type 2 diabetes.

Rebecca Taub, M.D., Vice President, Metabolic Diseases, Roche, USA

11:35 A Novel Therapeutic Target For Type II Diabetes

A novel protein has been discovered. Over-expression of this protein in both hepatocytes and adipocytes decreased activity of PPAR. Reciprocally, down-regulating the expression of this protein in adipocytes promoted the PPAR activity. The substrates of this protein enhanced adipogenesis and increase PPARα activity. The inhibitors and substrates of this protein may serve as a potential therapeutics for type II diabetes and related metabolic diseases.

Rong-Hwa Lin, Ph.D., CEO and Chairman, AbGenomics Corp., Taiwan

12:00 Technology Workshop

Sponsored by: Agilent Technologies

The Role and Workflow of Preparative HPLC (High Performance Liquid Chromatography) in Drug Discovery

Increasing demands on the purity of test compounds have given rise to the application of automated high throughput purification methods. The high performance and broad applicability of reversed-phase chromatography has led to the development of fully automated preparative liquid chromatography systems capable of purifying 250 compounds per day. At this Technology Workshop, we will be discussing the role and the workflow of preparative HPLC, aiding in drug discovery.

Udo Huber, Ph.D., Senior Application Chemist, Pharmaceutical Solutions Marketing, Agilent Technologies, Germany

12:30 Networking Luncheon in Exhibit & Poster Hall

2:00 New Paradigm in HIV Protease Inhibitor Therapy

To date, the development of primary resistance to lopinavir has not been observed in antiretroviral naïve patients in clinical trials for up to 6 years. Other protease inhibitors currently under development may offer improved antiviral activity against both wild type and PI-resistant HIV. These PIbs provides an example of new series of PIbs with potential for improved properties.

Akhter Molla, Ph.D., Senior Project Manager, Antiviral Research, Abbott Laboratories, USA

2:25 Challenges for R&D of Medicines for Tropical Diseases

Tropical disease burden in developing countries claims annually close to ten million lives. For new medicines against these diseases to be useful in developing countries they must satisfy specific requirements which must be taken into account at the earliest research stage. New ways must be found to develop safe and effective entities in a cost-effective manner.

Alex Matter, M.D., Director, Novartis Center for Tropical Diseases, Singapore

2:50 Development of Microarray Profiles for Influenza Virus Infection

The recent outbreaks of a highly pathogenic avian influenza virus in Asia remind us of the real threat of a future pandemic from avian influenza. Microarray profiles for influenza virus infection could lead to better understanding of host-pathogen interactions and identification of biomarkers for diagnostics and drug development. Microarray results in mice infected with influenza virus A will be presented.

Harry Zhang, Ph.D., Vice President and CSO, Z-BioMed Inc., USA

3:15 Emerging Epidemic of Metabolic Syndrome and Its Impact on Cardiovascular Disease

A collection of cardiovascular (CV) risk factors including, dyslipidemia, hypertension, obesity and insulin resistance are know to occur in patients with metabolic syndrome (MetS). Recent studies have demonstrated a significantly higher mortality due to CV events in adults with than without MetS. This talk will provide insight into the impact of MetS on CV disease and potential therapeutic intervention strategies.

Jai Pal Singh, Ph.D., Head of Cardiovascular Disease, Eli Lilly & Co., USA

3:40 Networking Refreshment Luncheon in Exhibit & Poster Hall

4:10 Exploitation of Leads and Chemical Tools in Translational Research for Psychiatry

Translational science is an emerging area that links preclinical laboratory research to clinical efficacy of compounds in human disease. This talk will describe new directions in the use of high throughput screening and adaptation of Lead Generation processes for the production of novel tool compounds at central nervous system targets, and their use in translational models with relevance to psychiatry.

Deborah Hartman, Ph.D., Director, Lead Discovery, AstraZeneca Pharmaceuticals, USA

4:35 Delivering siRNA in vivo for High-Value Target Validation and Development of Novel Therapeutics

We have developed a technology for siRNA delivery into tumor, lung, eyes, joint, liver and brain with efficient silencing activity. The technology not only allows us to establish platforms for in vivo target validation, but for development of novel therapeutics to treat cancer, SARS, AMD, hepatitis and CNS diseases. A ligand-directed nanoparticle for siRNA delivery efficiently into the diseased tissues has achieved a dual-targeted therapeutic effect. Based on a series of preclinical results, we are moving to clinical phase of siRNA-based therapeutic development.

Patrick Y. Lu, Ph.D., Executive Vice President, Intradigm Corporation, USA

5:00 The Discovery of Thrombin Receptor Antagonists for the Treatment of Thrombosis

Studies have suggested that thrombin receptor antagonists could be used to treat arterial thrombosis. At SPRI, we have discovered thrombin receptor antagonists from the structural modification of natural product himbacine. This talk will discuss our efforts in the discovery of potent and orally active compounds.

YüGuang Wang, Ph.D., Senior Principal Scientist, CV and CNS Discovery Research, Schering-Plough Research Institute, President, Tristate CACS, USA

5:25 Pre-Cocktail Keynote Address

Successful Deal-Making in a Rapidly Changing Licensing and Partnering Environment

In recent years, a number of changes have been observed in the pharmaceutical industry, especially with respect to partnering and licensing. This talk will discuss the driving forces and overall consequences, especially from the viewpoint of a multinational pharmaceutical company.

Klaus K. Wilgenbus, Head Corporate Division Licensing, Boehringer Ingelheim, Austria

This session is open to all registered attendees as well as exhibit hall visitors.

5:50 Networking Cocktail Reception in Exhibit & Poster Hall

7:00 Close of Exhibit & Poster Hall

Visit www.drugdisc.com/3110 for up-to-date information on this event
**Chairman's Opening Remarks**

E. Morrey Atkinson, Ph.D., Director, Bioprocess Research and Development, Eli Lilly & Company, USA

**Keynote Address**

Big Pharma: Can We Increase Productivity, If So How, and is the Current Big Pharma Business Model Sustainable?

Ismail Kola, Ph.D., SVP Basic Research, Merck Research Laboratories, United States

---

**Biopharmaceuticals/Biotechnology Research & Development**

**8:35 A Development and Production Platform for the Manufacture of a Wide Portfolio of Biopharmaceuticals**

Most biologics fall into key classes: peptides, monoclonal antibodies, and other recombinant proteins. An ideal integrated approach to development relies on statistically designed process experiments, common production, recovery and purification platforms, and fungible assets such as equipment and facilities. This enables the development of a wide portfolio of products, efficiently utilizing resources and minimizing overall risk.

E. Morrey Atkinson, Ph.D., Director, Bioprocess Research and Development, Eli Lilly & Company, USA

**9:00 Research for New Antibiotics: An Integrated Multidisciplinary Approach**

The presentation will overview the discovery and development process from the use of genomics to select targets, assay development and automation, high throughput screening and selection of hits, to chemical approaches employed to progress leads to the development stage and to generate novel antibiotics.

Khalil Islam, PhD, President and CEO, ARPIDA Ltd., Switzerland

**9:25 Rabbit Monoclonal Antibodies for Therapeutics and Diagnostics for Cancers and Inflammatory Diseases**

Like murine mAbs, RabMabs are likely to elicit an immune response in patients. We have demonstrated that RabMabs can be humanized to a very high degree of sequence similarity with human germline antibody sequences without significant loss of antigen binding affinity. We are currently evaluating the technical feasibility of isolating high performance humanized RabMabs against known therapeutic targets and here we report the isolation and characterization of approximately 50 anti-TNFa neutralizing RabMabs.

Guo-Liang Yu, Ph.D., President & CEO, Epitomics Inc., USA

**10:45 Enhancement of Protein Stability by Polyethylene Glycol Conjugation: Implications for Biopharmaceutical Development**

Improving protein stability is of great importance for biopharmaceutical development. This presentation will discuss the benefits obtained by polyethylene glycol (PEG) conjugation to proteins, focusing on solubility and bioavailability. Recent results obtained using Neulasta as a case study will be highlighted.

Rahul S. Rajan, Ph.D., Scientist, Amgen Inc., USA

---

**Surface Activity & Novel Drug Delivery Systems for Biotherapeutics**

The exploration of principles of surface activity for therapeutics has proved to be quite interesting and rewarding. Beginning with simple suspensions and emulsions the principles of surface activity are making advancement in to sophisticated drug delivery systems like Microemulsion (ME) liposome, noisome, polymeric micelles and self-emulsifying drug delivery systems (seds). The role of surface activity is also explored to improve and alter PK and PD properties of biopharmaceuticals. The therapeutic benefits achieved relate to improved bioavailability and reduced toxicity.

Anantha Naik Nagappa, Ph.D., Professor, Pharmacy Group, Birla Institute of Science & Technology, India

---

**Harnessing Published Information for Better Drug Discovery ROI and Smarter Decisions**

In this presentation, we will examine results of studies comparing the use of integrated versus other non-integrated sources to answer real-life discovery questions, and will report on studies of typical searching workflows and strategies used by scientists, and how these can be fine tuned for more effective information retrieval and decision support.

William H. Balke, Ph.D., Vice President, Emerging Markets, Elsevier MDL, USA

---

**Natural Products Drug Discovery**

**2:05 A New Model for Utilising Natural Products for Drug Discovery**

The pressing need to fill drug development pipelines, combined with the paucity of novel lead compounds, is prompting many pharma companies to re-evaluate the utility of natural products as sources of novel chemistry. Through a judicious combination of new technologies and compelling business models, cost effective solutions are available for accessing the unique chemical diversity found in Nature.

Tony Buss, Ph.D., President & CEO, MerLion Pharmaceuticals, Singapore
2:30 Drug Discovery from Nature for Innovative Therapeutic Concepts
Natural products have a uniquely successful track record in the pharmaceutical business. By examples of recent launches or compounds now at advanced stages in research or clinical development, it will be highlighted what opportunities are generated when natural products are in the portfolio of drug discovery.
Frank Petersen, Ph.D., Executive Director & Head Natural Products Unit, Novartis AG, Switzerland

Clinical Trials

2:55 West Meets East: Cultural Challenges for European and American Companies Engaging in Drug Development in Asia Pacific
For several reasons, European and American pharmaceutical companies are extremely interested in developing drugs in Asia-Pacific countries. However, in Western companies, there is a relative lack of cultural competency needed to understand the worldviews of prospective Asia-Pacific development partners. My presentation will address specific situations where cultural understanding is crucial for establishing business partnerships in clinical trial research.
Rocco Zaninelli, M.D., Executive Director, Clinical Research, Novartis, USA

3:20 Clinical Trial Design – A New Approach
Clinical development represents the longest and most expensive part of drug development. With the emergence of a new group of antiancancer drugs that specifically target cancer, clinical development can now be tailored around the properties of investigational medicines by preserving the principals but altering the design of standard phase I-III studies. This approach could provide faster development, more certainty and lower cost.
Miroslav Ravic, M.D., Ph.D., Chief Clinical Officer, Antisoma, UK

3:45 Networking Refreshment Break

4:15 Human Microdosing: The Increasing Importance of Early Human Data for More Cost-Effective and Timely Drug Development
Drug development costs are soaring; late stage failures are high and new drug approvals are declining. Human microdosing allows low doses of drug candidates to be administered before Phase I trials to obtain early human PK and ADME data. This novel approach enables early selection of the best candidates to take forward with a greatly enhanced chance of success.
Paul J Clewlow, Ph.D., Business Development Director, Pharmaceutical Profiles, UK

4:40 Clinical Development in Asia: From Launch to Completion - Management Perspectives
With the increasing trend towards globalization and more specifically, the need for shorter time spans in competing product development programs, there is an increasing need to find new sources of patients in meeting these objectives, notwithstanding the fact that some disease conditions are found in specific locations around the globe. Asia is fast becoming an area for such clinical development and an appreciation for the inherent intra-regional differences in infrastructure, regulatory requirements, know-how and cost structures play a significant role in successfully completing such an undertaking.
T Mahendran, B. Pharm (Hons.), MBA, Scientific Affairs Director, ALTANA Pharma Regional Office – Asia, Malaysia

5:05 The Asia Experience: Hurdles, Teamwork and Collaboration
• Hurdles: Vaccine shortage, daily changing and shortened timelines, multiple time zones around the world
• Teamwork: Enrolled 8,500 subjects in 10 days.
• Collaboration: MEDIMMUNE partnered with PPD for all non-Asian countries and Quintiles for Asia. Clinical supplies were labeled, packaged, coordinated and shipped by Cardinal and Quintiles.
Connie Andrews, Global Head Clinical Operations, MedImmune Inc., USA

5:30 Running International Clinical Trials: Special focus on the Asia-Pacific Region and China
The Asia-Pacific region is increasingly attractive to multinational biopharmaceutical companies for reasons including more rigorous patent protection laws, increase in disposable income, improved medical and scientific infrastructure, large treatment-naïve patient populations and cost advantages. As global R&D spending is set to increase by 12% in the next year with an increased percentage of this directed to the Asia Pacific region, this presentation will discuss the development of clinical trials in this region.
Mun Ching Kan, Client Relationship Director, Asia Pacific, Covance (Asia) Pte. Ltd., Singapore

5:55 Close of Conference
## Drug Discovery & Development Asia Pacific

**Product Code: 3110 A B C**

<table>
<thead>
<tr>
<th>First Name</th>
<th>Last Name</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Title</th>
<th>E-mail</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Company</th>
<th>Department</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Street Address</th>
<th>City</th>
<th>State</th>
<th>Zip</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Telephone</th>
<th>Fax</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Data Protection:** The personal information shown on this brochure, and/or provided by you, will be held on a database and may be shared with companies in the Informa Group. Sometimes your details may be obtained from, or made available to, external companies for marketing purposes. If you do not wish for your details to be used for this purpose, please email data-admin@ibcusa.com

---

<table>
<thead>
<tr>
<th>Registration Fees</th>
<th>Commercial</th>
<th>Early Bird***</th>
<th>Academic/Govt**</th>
<th>Early Bird***</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Full Conference Pass</strong> (Wed.-Fri., June 1-3)</td>
<td>$US1179</td>
<td>$US999</td>
<td>$US599</td>
<td>$US1791</td>
</tr>
<tr>
<td><strong>Scientific Symposium</strong> (Thur.-Fri., June 2-3)</td>
<td>$US813*</td>
<td>$US899</td>
<td>$US813*</td>
<td>$US899</td>
</tr>
</tbody>
</table>

**Exhibit Hall Only Pass**

| Reserve A Posterboard | $50 (S$82) | $35 (S$51) | FREE | FREE |

*Singapore Residents add 4% GST to this rate
**Rate is extended to full-time employees of government, universities and university affiliated hospitals who have NO affiliation to a for profit or commercial organization.
***For Early Bird Discount, register by April 1, 2005.

For on-site registration, please add $110 to the total fee. Prices include lunch, reception, refreshments and speaker documentation.

For security precautions, a photo identification will be required of ALL attendees at check-in.

---

**How to Register**

**Online**
[www.drugdisc.com/3110](http://www.drugdisc.com/3110)

**Mail**
IBC Asia (S) PTE LTD, No. 1 Grange Road #08-02 Orchard Building, Singapore 239693

**Tel/Fax** +65 6732 1970 / +65 6733 5087

**E-Mail** enquiry@ibcasia.com.sg

**U.S.A. contact for General Information:** Mimi Quek, Tel: 508-614-1255, email: mquek@ibcusa.com

---

**Team Discount – Register 2, the 3rd attends FREE!**

When two members of the same company register for the conference at the same time, the third attends FREE!

Complete registration forms for all parties must be sent together with complete payments for the entire group to qualify for team discounts.

---

**Payment** (required in advance of the conference)

- Mastercard
- Visa
- American Express
- Check
- Wire Transfer

Payments by US$ / S$ bank draft or cheque should be made in favour of “IBC Asia (S) Pte Ltd” payable in Singapore. Payment by Telegraphic transfer in US$ or S$ must be made to: IBC Asia (S) Pte Ltd, A/C No: 129-900-273-5 (US$), A/C No: 129-308-147-1 (S$), United Overseas Bank Ltd, Mt Elizabeth #01-03, Mt Elizabeth Medical Centre, Singapore 228510.

---

**Contact Information**

**U.S.A.**
IBC USA Conferences, Inc.
One Research Drive, Suite 400 A
P.O. Box 5195
Westborough, MA 01581-5195, U.S.A.

**Tel:** 508-614-1255, **Fax:** 508-614-1256

**Email:** mquek@ibcusa.com

**Website:** [www.drugdisc.com](http://www.drugdisc.com)

---

**Advancing Biomedical Research through Global Collaborations**

**Drug Discovery & Development**

**Asia Pacific**

---

**International Scientific Advisory Board**

- George Poste, Ph.D., Arizona Bodesign Institute, USA
- Lee Babiss, Ph.D., Vice President of Preclinical R & D, Hoffmann La-Roche, USA
- YuGuang Wang, Ph.D., Senior Principal Scientist, Schering-Plough, USA
- Harry (Hong) Zhang, Ph.D., Vice President & Chief Scientific Officer, Z-BioMed Inc., USA
- Li Chen, Ph.D., Head of Research, Roche, China
- Fumio Suzuki, Senior Executive Officer, Strategy Planning, Kyowa Hakko Kogyo Co., Ltd, Japan
- Alfred Scheidegger, Ph.D., Founding Partner & CEO, Nextech Venture AG, Switzerland
- Lorenz Mayr, Ph.D., Technology Manager, Novartis AG, Switzerland
- John Zawad, Ph.D., Vice President, Aventis Capital, USA
- Margaret Flanagan, Ph.D., Global Alliance Director, Global Sciences and Information, AstraZeneca, USA
- Ge Li, Ph.D., CEO, WuXi Pharmaceuticals, China
- Richard Soll, Ph.D., Chief Scientific Officer, TargeGen, USA

---

**www.drugdisc.com**

---

**IBC USA Conferences, Inc.**

---

**Drug Discovery & Development Asia Pacific**

---

**In Association with:**

- **SCRIP**
- **PRRT STD**
- **US Postage**
- **PAID**
- **IBC USA**

---

**June 1-3, 2005**

**Shangri-La Hotel Singapore**